Ticagrelor,a P2Y12 platelet inhibitor, is prescribed for individualswith prior myocardial infarction (MI) or with acute coronary syndrome(ACS) to diminish the risk of future MI, stroke, and cardiovascularmortality. This evidence concerns the gene P2RY12 and acute coronary syndrome.